Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2026
Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.
Journal: Journal for immunotherapy of cancer
Published: March 26, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: February 16, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.
Journal: Nature communications
Published: July 28, 2025
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.
Journal: Cancer chemotherapy and pharmacology
Published: July 18, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
Journal: Targeted oncology
Published: February 03, 2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 03, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.
Journal: BJC reports
Published: August 15, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Journal: Journal for immunotherapy of cancer
Published: July 18, 2024
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Journal: Investigational new drugs
Published: November 22, 2023
Last Updated: 09/26/2026